GOSS
Not the kind of follow-up you want
Gossamer Bio is dealing with more than just a bad day in the market. The company is now the target of a securities litigation investigation after the latest trial disappointment, which is basically the corporate version of getting kicked while you’re already down.
The stock got cratered
The article says the stock fell from $2.13 on February 20, 2026, to $0.42 a share — a gut-punch decline of more than 80% in a single session. That kind of move doesn’t just scare traders; it can rewrite the whole investment case in one afternoon.
Why investors should care
Cantor Fitzgerald also cut Gossamer to Neutral from Overweight, saying the negative Phase 3 readout for PROSERA and the murky regulatory path for seralutinib make it hard to have conviction in a clean path to commercialization.
That’s the key issue here: this isn’t just about one failed trial. It’s about whether the company can still point investors toward a believable road to approval, revenue, and maybe someday, actual calm.
Big picture
When a biotech loses clinical momentum, the lawyers often show up right behind the red candles. That doesn’t guarantee a disaster, but it does mean the market is now pricing in a lot more than just science risk.